{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T02:12:04Z","timestamp":1794363124862,"version":"4.9.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T00:00:00Z","timestamp":1557792000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T00:00:00Z","timestamp":1557792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81472453"],"award-info":[{"award-number":["81472453"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Major Project of Beijing Municipal Science and Technology Commission","award":["D161100000816004"],"award-info":[{"award-number":["D161100000816004"]}]},{"name":"CAMS Initiative for Innovative Medicine","award":["CAMS-12M-1-010, 2017-I2M-3-004"],"award-info":[{"award-number":["CAMS-12M-1-010, 2017-I2M-3-004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5668-3","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T11:03:52Z","timestamp":1557831832000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study"],"prefix":"10.1186","volume":"19","author":[{"given":"Zongbi","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9432-1902","authenticated-orcid":false,"given":"Fei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binliang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuwen","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haili","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,14]]},"reference":[{"issue":"12","key":"5668_CR1","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/ng.2823","volume":"45","author":"DR Robinson","year":"2013","unstructured":"Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446\u201351.","journal-title":"Nat Genet"},{"issue":"5","key":"5668_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrc3920","volume":"15","author":"CX Ma","year":"2015","unstructured":"Ma CX, Reinert T, Chmielewska I, Ellis MJ. Mechanisms of aromatase inhibitor resistance. Nat Rev Cancer. 2015;15(5):261\u201375.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"5668_CR3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1177\/1758834014530023","volume":"6","author":"E Paplomata","year":"2014","unstructured":"Paplomata E, O'Regan R. The PI3K\/AKT\/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol. 2014;6(4):154\u201366.","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"5668_CR4","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10549-010-0986-9","volume":"128","author":"N Margariti","year":"2011","unstructured":"Margariti N, Fox SB, Bottini A, Generali D. \u201cOvercoming breast cancer drug resistance with mTOR inhibitors\u201d. Could it be a myth or a real possibility in the short-term future? Breast Cancer Res Treat. 2011;128(3):599\u2013606.","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"5668_CR5","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","volume":"30","author":"DA Yardley","year":"2013","unstructured":"Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, et al. Everolimus plus Exemestane in postmenopausal patients with HR+ breast Cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30(10):870\u201384.","journal-title":"Adv Ther"},{"issue":"12","key":"5668_CR6","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1093\/annonc\/mdu456","volume":"25","author":"M Piccart","year":"2014","unstructured":"Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2\u2020. Ann Oncol. 2014;25(12):2357\u201362.","journal-title":"Ann Oncol"},{"issue":"22","key":"5668_CR7","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","volume":"30","author":"T Bachelot","year":"2012","unstructured":"Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero J, Freyer G, et al. Randomized phase II trial of Everolimus in combination with tamoxifen in patients with hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative metastatic breast Cancer with prior exposure to aromatase inhibitors: A GINECO study. J Clin Oncol. 2012;30(22):2718\u201324.","journal-title":"J Clin Oncol"},{"issue":"3","key":"5668_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/bcr3658","volume":"16","author":"LG Martelotto","year":"2014","unstructured":"Martelotto LG, Ng CKY, Piscuoglio S, Weigelt B, Reis-Filho JS. Breast cancer intra-tumor heterogeneity. Breast Cancer Res: BCR. 2014;16(3):210.","journal-title":"Breast Cancer Res: BCR"},{"issue":"4","key":"5668_CR9","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1172\/JCI44145","volume":"121","author":"SA Wander","year":"2011","unstructured":"Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Investig. 2011;121(4):1231\u201341.","journal-title":"J Clin Investig"},{"issue":"19","key":"5668_CR10","doi-asserted-by":"publisher","first-page":"8022","DOI":"10.1158\/0008-5472.CAN-08-1385","volume":"68","author":"V Serra","year":"2008","unstructured":"Serra V, Markman B, Scaltriti M, Eichhorn PJA, Valero V, Guzman M, et al. NVP-BEZ235, a dual PI3K\/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of Cancer cells with activating PI3K mutations. Cancer Res. 2008;68(19):8022\u201330.","journal-title":"Cancer Res"},{"issue":"4","key":"5668_CR11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ctrv.2012.11.002","volume":"39","author":"AM Gonzalez-Angulo","year":"2013","unstructured":"Gonzalez-Angulo AM, Blumenschein GJ. Defining biomarkers to predict sensitivity to PI3K\/Akt\/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev. 2013;39(4):313\u201320.","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"5668_CR12","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1200\/JCO.2011.36.1196","volume":"30","author":"F Janku","year":"2012","unstructured":"Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, et al. PI3K\/AKT\/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012;30(8):777\u201382.","journal-title":"J Clin Oncol"},{"issue":"5","key":"5668_CR13","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.2014.60.1971","volume":"34","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Chen D, Piccart M, Rugo HS, Burris HR, Pritchard KI, et al. Correlative analysis of genetic alterations and Everolimus benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast Cancer: results from BOLERO-2. J Clin Oncol. 2016;34(5):419\u201326.","journal-title":"J Clin Oncol"},{"issue":"6","key":"5668_CR14","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/bjc.2017.25","volume":"116","author":"ME Moynahan","year":"2017","unstructured":"Moynahan ME, Chen D, He W, Sung P, Samoila A, You D, et al. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2. Br J Cancer. 2017;116(6):726\u201330.","journal-title":"Br J Cancer"},{"issue":"15","key":"5668_CR15","doi-asserted-by":"publisher","first-page":"4173","DOI":"10.1158\/1078-0432.CCR-12-0714","volume":"18","author":"DS Hong","year":"2012","unstructured":"Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, et al. A multicenter phase I trial of PX-866, an Oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2012;18(15):4173\u201382.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"5668_CR16","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1158\/1078-0432.CCR-09-2828","volume":"16","author":"C O'Brien","year":"2010","unstructured":"O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, Punnoose EA, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3\u2032 kinase inhibitor GDC-0941 in breast Cancer preclinical models. Clin Cancer Res. 2010;16(14):3670\u201383.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"5668_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, A PTBJ, Dancey J, G SAHS, Kaplan R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"1","key":"5668_CR18","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1038\/s41467-018-05327-w","volume":"9","author":"J Nong","year":"2018","unstructured":"Nong J, Gong Y, Guan Y, Yi X, Yi Y, Chang L, Yang L, Lv J, Guo Z, Jia H, et al. Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nat Commun. 2018;9(1):3114.","journal-title":"Nat Commun"},{"issue":"1","key":"5668_CR19","doi-asserted-by":"publisher","first-page":"5995","DOI":"10.1038\/s41598-017-06327-4","volume":"7","author":"Z Yi","year":"2017","unstructured":"Yi Z, Ma F, Li C, Chen R, Yuan L, Sun X, Guan X, Li L, Liu B, Guan Y, et al. Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis. Sci Rep. 2017;7(1):5995.","journal-title":"Sci Rep"},{"issue":"4","key":"5668_CR20","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jmoldx.2017.04.007","volume":"19","author":"X Yang","year":"2017","unstructured":"Yang X, Chu Y, Zhang R, Han Y, Zhang L, Fu Y, Li D, Peng R, Li D, Ding J, et al. Technical validation of a next-generation sequencing assay for detecting clinically relevant levels of breast Cancer-related single-nucleotide variants and copy number variants using simulated cell-free DNA. J Mol Diagn. 2017;19(4):525\u201336.","journal-title":"J Mol Diagn"},{"issue":"3","key":"5668_CR21","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.ygyno.2012.08.040","volume":"127","author":"F Zagouri","year":"2012","unstructured":"Zagouri F, Sergentanis TN, Chrysikos D, Filipits M, Bartsch R. mTOR inhibitors in breast cancer: a systematic review. Gynecol Oncol. 2012;127(3):662\u201372.","journal-title":"Gynecol Oncol"},{"issue":"35","key":"5668_CR22","doi-asserted-by":"publisher","first-page":"59810","DOI":"10.18632\/oncotarget.16336","volume":"8","author":"C Gong","year":"2017","unstructured":"Gong C, Zhao Y, Wang B, Hu X, Wang Z, Zhang J, Zhang S. Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study. Oncotarget. 2017;8(35):59810\u201322.","journal-title":"Oncotarget"},{"key":"5668_CR23","first-page":"8692343","volume":"2016","author":"Y Luo","year":"2016","unstructured":"Luo Y, Feng M, Fan Z, Zhu X, Jin F, Li R, Wu J, Yang X, Jiang Q, Bai H, et al. Effect of Kangfuxin solution on chemo\/radiotherapy-induced mucositis in nasopharyngeal carcinoma patients: A multicenter, prospective randomized phase III clinical study. Evid Based Complement Alternat Med. 2016;2016:8692343.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"7","key":"5668_CR24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s12032-016-0788-y","volume":"33","author":"F Ahmad","year":"2016","unstructured":"Ahmad F, Badwe A, Verma G, Bhatia S, Das BR. Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients. Med Oncol. 2016;33(7):74.","journal-title":"Med Oncol"},{"issue":"10","key":"5668_CR25","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1093\/annonc\/mds075","volume":"23","author":"C Villarreal-Garza","year":"2012","unstructured":"Villarreal-Garza C, Cortes J, Andre F, Verma S. mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions. Ann Oncol. 2012;23(10):2526\u201335.","journal-title":"Ann Oncol"},{"issue":"6","key":"5668_CR26","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.2010.33.5232","volume":"30","author":"E Amir","year":"2012","unstructured":"Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, Oldfield M, Dranitsaris G, Tomlinson G, Laupacis A, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol. 2012;30(6):587\u201392.","journal-title":"J Clin Oncol"},{"issue":"6","key":"5668_CR27","doi-asserted-by":"publisher","first-page":"7033","DOI":"10.1007\/s13277-016-4924-2","volume":"37","author":"E Dirican","year":"2016","unstructured":"Dirican E, Akkiprik M, Ozer A. Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer. Tumour Biol. 2016;37(6):7033\u201345.","journal-title":"Tumour Biol"},{"issue":"1","key":"5668_CR28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/PDM.0b013e318297afea","volume":"22","author":"R Arsenic","year":"2014","unstructured":"Arsenic R, Lehmann A, Budczies J, Koch I, Prinzler J, Kleine-Tebbe A, Schewe C, Loibl S, Dietel M, Denkert C. Analysis of PIK3CA mutations in breast cancer subtypes. Appl Immunohistochem Mol Morphol. 2014;22(1):50\u20136.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"8 Supplement","key":"5668_CR29","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1158\/1538-7445.AM2011-4485","volume":"71","author":"David J. Matthews","year":"2011","unstructured":"Matthews D, O Farrell M, Joyce J, Stott G, Giddens A, Rewcastle GEA. Preclinical characterization of PWT33597, a dual inhibitor of PI3-kinase alpha and mTOR. Proceedings Am Assoc Cancer Res 102nd Annual Meet. 2011:4485.","journal-title":"Cancer Research"},{"issue":"1","key":"5668_CR30","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/0008-5472.CAN-12-1726","volume":"73","author":"F Janku","year":"2013","unstructured":"Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, et al. PIK3CA mutation H1047R is associated with response to PI3K\/AKT\/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 2013;73(1):276\u201384.","journal-title":"Cancer Res"},{"issue":"5","key":"5668_CR31","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1073\/pnas.0510857103","volume":"103","author":"AG Bader","year":"2006","unstructured":"Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A. 2006;103(5):1475\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"5668_CR32","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/annonc\/mdu497","volume":"26","author":"I Treilleux","year":"2015","unstructured":"Treilleux I, Arnedos M, Cropet C, Wang Q, Ferrero JM, Abadie-Lacourtoisie S, Levy C, Legouffe E, Lortholary A, Pujade-Lauraine E, et al. Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer. Ann Oncol. 2015;26(1):120\u20135.","journal-title":"Ann Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5668-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5668-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5668-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T23:10:42Z","timestamp":1589325042000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5668-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,14]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5668"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5668-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,14]]},"assertion":[{"value":"27 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was reviewed and approved by the ethics committee at the National Cancer Center\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. The collection and sequencing of peripheral blood samples of patients who consented to participate in ctDNA analysis were approved by the ethics committee (ref: 16\u2013038\/1117). Written informed consent was obtained from all patients who participated in the ctDNA analysis. Due to the retrospective approach of this study, the need for informed consent from patients who did not participate int he ctDNA analysis was waived by the ethics committees.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"442"}}